The forecast for beta-blocking medicine sales in Italy from 2024 to 2028 indicates a consistent share of 1.6% of total sales, with no year-on-year variations identified over this period. This stability reflects an unchanging demand or sales environment following the actual data from 2023. Without fluctuation or growth, a Compound Annual Growth Rate (CAGR) analysis remains unchanged at 0% over the five-year period, indicating a plateau in market dynamics.

Future trends to watch for include:

Potential policy changes in the Italian healthcare system impacting beta-blocker prescriptions.
Advancements in cardiovascular treatments that could introduce competitive alternatives to beta blockers.
Shifts in population health demographics, influencing long-term demand.